BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wongseelashote S, Tayal V, Bourke PF. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016. Intern Med J 2018;48:165-72. [PMID: 28742259 DOI: 10.1111/imj.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Xu C, Goh KL, Abeyaratne A, Priyadarshana K. Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia - a single centre study retrospective study. BMC Nephrol 2022;23:235. [PMID: 35787253 DOI: 10.1186/s12882-022-02849-w] [Reference Citation Analysis]
2 Choi SH, Yoon CH, Lee HJ, Kim HP, Kim JM, Che JH, Roh KM, Choi HJ, Kim J, Hwang ES, Park CG, Kim MK. Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation. Xenotransplantation 2018;25:e12442. [PMID: 30264877 DOI: 10.1111/xen.12442] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Howe K, Bourke S, Sansom L. The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review. PLoS One 2021;16:e0261022. [PMID: 34860857 DOI: 10.1371/journal.pone.0261022] [Reference Citation Analysis]
4 Zhang E, Wu Y, Chen C, Wei R, Zhang J, Xie H, Wei C, Ma L, Dong X, Li R, Zhou Y, Cui Y, Wu Y. Effect of different initial rituximab regimens on B cell depletion in children with autoimmune neurological diseases. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103510] [Reference Citation Analysis]
5 Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev 2021;11:CD013874. [PMID: 34748215 DOI: 10.1002/14651858.CD013874.pub2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]